What are the opening hours?

Monday 9am - 1pm 2pm - 5:30pm Tuesday 9am - 1pm 2pm - 5:30pm Wednesday 9am - 1pm 2pm - 5:30pm Thursday 9am - 1pm 2pm - 5:30pm

Gerti Tashko, M.D.

Home
United States
Rockville, MD
Gerti Tashko, M.D.

• Endocrinology, Diabetes and Metabolism
• Obesity Medicine
• Hypertension
• Lipidology

http://www.healthgrades.com/physician/dr-gerti-tashko-xkycy

http://www.vitals.com/doctors/Dr_Gerti_Tashko/reviews

02/10/2026

Oral PCSK9 inhibition represents a major advance in cholesterol care. This new study shows that enlicitide delivers deep and durable LDL reductions without injections. By combining strong biologic effect with daily oral dosing, enlicitide expands personalized options for patients with ASCVD or high cardiovascular risk who remain above LDL targets despite standard therapy.

↘️ Why Oral PCSK9 Therapy Matters
↘️ Study Design and Population
↘️ LDL Cholesterol Reduction and Durability
↘️ Effects on ApoB, Non-HDL Cholesterol, and Lipoprotein(a)
↘️ Safety and Tolerability Profile
↘️ How This Compares With Existing Lipid Therapies
↘️ Comparison With the Prior HeFH-Focused Enlicitide Data
↘️ Summary Table: Key Trial Findings
↘️ Patient Cases That Reflect Real Practice
↘️ Integrating Enlicitide Into Thoughtful Care

Read More ⤵️

Dr. Tashko reviews the NEJM enlicitide trial, explaining how oral PCSK9 therapy lowers LDL powerfully without injections.

02/07/2026

Plozasiran and olezarsen are RNA-based therapies that lower ApoC-III to improve triglyceride metabolism. Although both reduce triglycerides substantially, they act through different molecular pathways. This article explains how siRNA and antisense therapies differ, including where they work in the cell, which RNA they target, and why dosing schedules vary.

↘ Why ApoC-III Is a Key Metabolic Brake
↘ Plozasiran: Acting on Mature mRNA in the Cytoplasm
↘ Olezarsen: Acting Earlier in the Nucleus
↘ Simple Mechanistic Comparison
↘ Clinical Impact Remains Similar
↘ Patient Scenarios in Everyday Practice
↘ Choosing Between Two Effective Strategies

Read More ⤵

Dr. Tashko explains how plozasiran and olezarsen lower ApoC-III through different RNA mechanisms and what that means for triglyceride care.

02/06/2026

RNA interference medications represent a major shift in lipid therapy. By silencing hepatic genes before proteins form, RNAi therapies deliver durable LDL cholesterol, lipoprotein(a), and triglyceride lowering with infrequent dosing. These treatments move beyond surface-level inhibition and offer new options for patients with residual cardiovascular risk, adherence challenges, or genetically driven lipid disorders.

↘ The Biological Logic Behind RNA Interference
↘ Why Hepatocyte Targeting Changes Everything
↘ Key Pathways Targeted by RNAi Lipid Drugs
↘ How RNAi Differs Conceptually From Other Therapies
↘ Why Infrequent Dosing Is Not a Convenience Feature
↘ Clinical Rationale Within a Broader Strategy
↘ Patient Cases Illustrating Real-World Impact
↘ Summary Table: RNAi Lipid Therapies
↘ Looking Ahead

Read More ⤵

Dr. Tashko explains RNA interference lipid medications, including siRNA therapies for LDL cholesterol, lipoprotein(a), and triglycerides.

02/03/2026

RNA interference is a natural gene silencing process now used in modern medicine. By targeting messenger RNA before proteins form, RNAi therapies reduce disease driving proteins with precision and durability. This article explains how RNA interference works, how it differs from traditional medications, and where it fits in lipid management, metabolic care, and emerging clinical applications.

↘️ What Is RNA Interference
↘️ The Core Mechanism of RNA Interference
↘️ Why RNA Interference Differs From Traditional Drugs
↘️ RNA Interference Compared With Traditional Therapies
↘️ Delivery Challenges and Breakthroughs
↘️ Current Clinical Applications of RNA Interference
↘️ Patient Scenarios Illustrating RNA Interference Use
↘️ Advantages and Limitations to Consider
↘️ The Future of RNA Interference in Medicine
↘️ Takeaway

Read More ⤵️

Dr. Tashko explains RNA interference, gene silencing mechanisms, and how RNAi therapies are used in cholesterol and metabolic care.

02/02/2026

Severe hypertriglyceridemia carries a real risk of acute pancreatitis. New research shows that olezarsen, a targeted apoC-III inhibitor, can dramatically lower triglycerides and reduce pancreatitis events. This article explains the biology behind triglyceride driven pancreatitis and how this new therapy changes prevention strategies for high risk patients.

↘ Why Severe Hypertriglyceridemia Causes Pancreatitis
↘ The Central Role of Apolipoprotein C-III
↘ How Olezarsen Works
↘ Design of the CORE-TIMI 72a and 72b Trials
↘ Core Findings at a Glance
↘ Triglyceride and Lipid Outcomes
↘ Reduction in Pancreatitis Risk
↘ Safety and Dose Considerations
↘ Patient Scenarios Seen in Practice
↘ Clinical Implications

Read More ⤵

Dr. Tashko explains how olezarsen lowers severe triglycerides and meaningfully reduces pancreatitis risk through targeted apoC-III inhibition.

01/30/2026

This recent randomized study shows that oats lower cholesterol through more than fiber alone. Gut microbes transform oat phenolic compounds into active metabolites that directly influence LDL cholesterol. The findings explain why oat responses vary between individuals and why dose and dietary context matter. This research reframes oats as a microbiome active food with meaningful metabolic impact.

↘ Why This Study Matters for Metabolic Health
↘ Study Design in Plain Terms
↘ What Changed After Just Two Days of Oats
↘ The Role of Phenolic Metabolites
↘ Why the Gut Microbiome Matters
↘ What About the Six-Week Moderate Oat Diet
↘ Mechanistic Insights Beyond Fiber
↘ Patient Scenarios Seen in Practice
↘ Key Takeaways for Thoughtful Care

Read More ⤵

Dr. Tashko explains how oats lower cholesterol through gut microbiome derived metabolites and what this study means for metabolic health.

01/25/2026

Most lab reports show TSH as a single normal range. In real care, that range behaves more like a curve. It shifts with age, heart risk, bone health, pregnancy, and symptoms. Functional thyroid zones help align lab targets with biology. The goal is not a perfect number. The goal is physiology that supports how each individual actually functions.

↘ The Concept in Brief
↘ Functional Zones in Practice
↘ How I Apply This Clinically
↘ When to Tighten or Loosen Targets
↘ How I Explain This to Patients

Read More ⤵

Dr. Tashko explains personalized TSH targets using thyroid functional zones to guide safer, individualized hypothyroidism care.

01/23/2026

Respiratory syncytial virus causes serious illness and hospitalization in older adults. New randomized data now show that RSV vaccination significantly reduces RSV related hospitalizations and severe respiratory outcomes. This article explains how RSV vaccines work, who benefits most, and how new evidence may change current clinical practice for adults aged 60 and older.

↘ Understanding RSV in Adults
↘ A Brief History of RSV Vaccine Development
↘ FDA Approval and Available RSV Vaccines
↘ Current RSV Vaccination Guidelines
↘ Why Hospitalization Prevention Matters
↘ Overview of the New Study
↘ Key Findings in Plain Language
↘ Summary Table: RSV Vaccination Outcomes in Older Adults
↘ Why This Study Matters Clinically
↘ How This Could Change Current Practice
↘ A Practical Takeaway

Read More ⤵

Dr. Tashko explains how RSV vaccination reduces hospitalization risk in older adults and how new evidence may change current RSV prevention strategies.

01/20/2026

Omega 3 fatty acids are essential nutrients with powerful anti-inflammatory effects. A major NEJM trial now shows that fish-oil supplementation significantly reduces cardiovascular events in patients receiving hemodialysis. This patient-focused summary explains how omega 3 works, why dialysis patients face extreme heart risk, and how targeted supplementation may offer meaningful protection when few therapies exist.

↘ Why Cardiovascular Risk Is So High in Hemodialysis
↘ Overview of the PISCES Trial
↘ What Outcomes Did the Study Measure?
↘ Key Results in Plain Language
↘ Summary of Major Findings
↘ Why Might Omega-3s Work in Dialysis Patients?
↘ How This Study Fits into the Broader Context
↘ Practical Takeaways for Patients and Clinicians
↘ Patient Case Examples
↘ Final Perspective

Read More ⤵

Dr. Tashko explains how omega 3 fish oil reduced cardiovascular events in hemodialysis patients, with clear clinical context and patient insight.

01/16/2026

The 2026 ADA diabetes guidelines move beyond rigid algorithms toward individualized care. Expanded CGM access, stronger obesity management, and broader use of GLP-1–based therapies reshape how diabetes is treated today. This patient-facing summary highlights the updates that most affect real-world care and long-term metabolic health.

↘ Quick Reference Table: What Changed and Why It Matters
↘ 1. A Stronger Emphasis on Shared Decision-Making
↘ 2. Earlier and Broader Use of Continuous Glucose Monitoring
↘ 3. Weight Management as a Central Therapeutic Pillar
↘ 4. GLP-1–Based Therapies Beyond Glucose Control
↘ 5. Liver Disease Enters the Main Algorithm
↘ 6. Cardiovascular Risk Targets Tighten Further
↘ 7. Heart Failure Gets Tailored Therapy
↘ 8. Kidney Protection Starts Earlier and Runs Deeper
↘ 9. Behavioral Health and Sleep Move to the Forefront
↘ 10. Older Adults Receive More Nuanced Targets
↘ Practical Patient Scenarios
↘ A Broader, More Integrated Vision of Diabetes Care

Read More ⤵

Dr. Tashko explains the key 2026 ADA diabetes guideline updates, focusing on CGM, weight management, GLP-1 therapy, and personalized care.

01/15/2026

I was honored to be featured in this Montgomery Magazine article.

It reflects how I think about health every day in practice, particularly for women who are asking not just how long they’ll live, but how well. I focus on the full picture rather than isolated numbers. Many patients feel confused or overwhelmed, and my goal is clarity and a smart strategy forward.

Sharing here in case it helps someone make sense of their own health journey.

In Montgomery County, more women are thinking not just about how long they’ll live, but how well.

01/14/2026

PCSK9 inhibitors represent a major advance in cholesterol management. The VESALIUS-CV trial shows that evolocumab reduces first cardiovascular events in patients with atherosclerosis or diabetes, even without a prior heart attack or stroke. These findings expand prevention strategies beyond traditional secondary prevention and support earlier, more personalized lipid lowering approaches.

↘ Why This Study Matters
↘ Study Design in Simple Terms
↘ Who Was Studied
↘ Key Results Explained Clearly
↘ Key Findings from the VESALIUS-CV Trial at a Glance
↘ Safety Findings
↘ How This Changes Prevention Thinking
↘ Patient Scenarios Where This Matters
↘ A Balanced Perspective
↘ Takeaway

Read More ⤵

Dr. Tashko reviews the VESALIUS-CV trial showing how evolocumab reduces first heart attacks and strokes through early LDL cholesterol lowering.

Address

15204 Omega Drive, Suite 240
Rockville, MD
20850

Opening Hours

Monday	9am - 1pm
	2pm - 5:30pm
Tuesday	9am - 1pm
	2pm - 5:30pm
Wednesday	9am - 1pm
	2pm - 5:30pm
Thursday	9am - 1pm
	2pm - 5:30pm

Telephone

+13016583586

Website

http://GertiTashkoMD.com/

Alerts

Be the first to know and let us send you an email when Gerti Tashko, M.D. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Want your practice to be the top-listed Clinic in Rockville?